Abbott To Acquire Cephea Valve Technologies, Inc.
Acquisition to further bolster Abbott's leading position in therapies for mitral valve disease, the most common type of heart valve ailment
ABBOTT PARK, Ill., Jan. 16, 2019 -- (Healthcare Sales & Marketing Network) -- Abbott (NYSE: ABT) announced today... Devices, Interventional, Cardiology, Mergers & Acquisitions Abbott, Cephea Valve Technologies, Mitral valve, heart valve (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 16, 2019 Category: Pharmaceuticals Source Type: news
Abbott To Acquire Cephea Valve Technologies, Inc.
Acquisition to further bolster Abbott's leading position in therapies for mitral valve disease, the most common type of heart valve ailment (Source: Abbott.com)
Source: Abbott.com - January 16, 2019 Category: Pharmaceuticals Source Type: news
AHA: Infection as a Baby Led to Heart Valve Surgery for Teen
WEDNESDAY, Jan. 16, 2019 (American Heart Association) -- In middle school, Prince Pratt used to get short of breath walking between classes, walking up the stairs or when exercising. And he was gaining weight.
His father, Reggie, simply thought his... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 16, 2019 Category: General Medicine Source Type: news
Abbott to acquire Cephea Valve Technologies, Inc.
Abbott (NYSE: ABT) announced today that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical device company developing a less-invasive heart valve replacement technology for people with mitral valve disease. Financial terms were not disclosed. Abbott provided capital and secured an option to purchase Cephea in 2015. (Source: World Pharma News)
Source: World Pharma News - January 16, 2019 Category: Pharmaceuticals Tags: Featured Abbott Business and Industry Source Type: news
Edwards Lifesciences pays $180m to bury the hatchet with Boston Scientific
Boston Scientific (NYSE:BSX) and Edwards Lifesciences (NYSE:EW) said today that they’re burying the hatchet, settling their worldwide patent war over cardiac valve and implant technology, with Edwards paying $180 million to end the dispute.
“All pending cases or appeals in courts and patent offices between the two companies will be dismissed, and the parties will not litigate patent disputes related to current portfolios of transcatheter aortic valves, certain mitral valve repair devices, and left atrial appendage closure devices. Any injunctions currently in place will be lifted,” the companies said to...
Source: Mass Device - January 15, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Cardiac Implants Featured Legal News Replacement Heart Valves Wall Street Beat Boston Scientific Edwards Lifesciences Source Type: news
3D-printed implants anchor spinal cord regeneration
Researchers from California have created 3D-printed implants modeled from MRI...Read more on AuntMinnie.comRelated Reading:
3D printing offers alternative to CT-guided lung surgery
3D printing technique improves heart valve sizing
3D head models reduce workload for brain radiotherapy
3D-printed device aids knee replacement surgery
3D-printed aortas could work well for TAVR (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 15, 2019 Category: Radiology Source Type: news
FDA Approves Abbott & #039;s Device for Treating Premies with an Opening in Their Hearts
Born at 27 weeks, twin babies Irie and Judah Felkner of Columbus, Ohio, were both fighting for their lives in the neonatal intensive care unit when an echocardiogram revealed Irie had a patent ductus arteriosus (PDA) that required immediate treatment.
"The doctor thought Abbott's Amplatzer Piccolo device was the best solution for Irie, and after learning more about the procedure we decided to move forward," said Crissa Felkner, Irie's mother. "You have to live it to fully appreciate what that device did for our daughter. Three days after the procedure, she was making great progress and is now a normal toddler with no limit...
Source: MDDI - January 14, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news
Hancock Jaffe sets endpoints for FIH VenoValve study
Hancock Jaffe Laboratories (NSDQ:HJLI) today announced the endpoints for its planned first-in-human study of its VenoValve device.
The VenoValve is a porcine valve designed to be implanted into the femoral or popliteal vein to treat lower limb chronic venous insufficiency from damage to leg vein valves after deep vein thrombosis, the Irvine, Calif.-based company said.
Endpoints for the study include improvements in reflux time measured by duplex scans and rVCSS, VAS and VEINES scores, which are used as clinical measurements for venous disease. Hancock Jaffe said that patients in the trial will be monitored at regular int...
Source: Mass Device - January 9, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Clinical Trials Replacement Heart Valves hancockjaffelabs Source Type: news
Thubrikar Aortic Valve launches Brazilian TAVR trial
Privately held medical device developer Thubrikar Aortic Valve said yesterday that it launched a Brazilian trial of its Optimum transcatheter aortic valve using the company’s implantation system.
The Norristown, Penn.-based company touted that the first human implant has been performed in the trial, which is being sponsored by the company’s Brazilian licensee, Labcor Laboratórios, who also manufactured the valve.
“We are very pleased to initiate this clinical trial of the licensed technology from Thubrikar and anticipate completion of the trial in 2019,” Labcor co-founder Dr. Ivan Casagrande said i...
Source: Mass Device - January 9, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Featured Replacement Heart Valves thubrikaraorticvalve Source Type: news
JC Medical touts first U.S. treatment with transfemoral TAVR system
JC Medical said today that the company’s first U.S.-based patient was treated with its transfemoral transcatheter aortic valve implant system, J-Valve TF.
The FDA approved the use of J-Valve for people with aortic regurgitation through its “compassionate use” pathway. JC Medical also noted that it’s gearing up for a clinical trial of the investigational device in the U.S. this year.
The first U.S. patient to use JC Medical’s J-Valve TF system was treated at The Christ Hospital in Cincinnati, Ohio by Dr. Dean Kereiakes, who serves as the medical co-director of the Lindner Research Center.
R...
Source: Mass Device - January 7, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Featured Replacement Heart Valves JC Medical Source Type: news
3D printing offers alternative to CT-guided lung surgery
An international team of researchers created 3D-printed navigational templates...Read more on AuntMinnie.comRelated Reading:
3D printing technique improves heart valve sizing
AR, 3D printing make headway in patient education
3D printing gives pediatric heart surgery a boost
3D-printed lungs improve patient understanding of surgery
3D head models reduce workload for brain radiotherapy (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 3, 2019 Category: Radiology Source Type: news
Edwards' SAPIEN 3 Ultra Transcatheter Heart Valve Receives FDA Approval
Irvine, Calif., Dec. 28, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the SAPIEN 3 Ultra system has received U.S. Food and Drug Administration (FDA) approval for transcatheter aortic valve replacement in severe, symptomatic aortic stenosis patients who are determined to be at intermediate or greater risk of open-heart surgery....This story is related to the following:Surgical Implants (Source: Industrial Newsroom - Health, Medical and Dental Supplies)
Source: Industrial Newsroom - Health, Medical and Dental Supplies - January 2, 2019 Category: Medical Devices Source Type: news
World surgical first sees 66-year-old blocked heart valve cleared with a live wire up his leg
Leaky heart valves can leave patients struggling for breath and lead to heart failure. Repair usually involves open heart surgery but Michael Hammond, of Hove, had an alternative. (Source: the Mail online | Health)
Source: the Mail online | Health - January 2, 2019 Category: Consumer Health News Source Type: news
FDA OKs Edwards' Sapien 3 Ultra Transcatheter Heart Valve FDA OKs Edwards' Sapien 3 Ultra Transcatheter Heart Valve
The advanced Sapien 3 Ultra system features enhancements of the valve and a new delivery system to address the needs of both patients and clinicians, the company says.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 31, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news
Edwards Heats up TAVR Market with New Approval
Edward Lifesciences’s long-awaited Sapien 3 Ultra transcatheter aortic valve replacement (TAVR) System has received a nod from FDA. The Irvine, CA-based company had received CE mark for the valve in November.
The Sapien 3 Ultra valve features a heightened outer skirt designed to eliminate paravalvular leak. The new delivery system introduces an "on balloon" design, removing the need for valve alignment during the procedure.
"The advanced Sapien 3 Ultra system features enhancements on the valve and a new delivery system to address the needs of both patients and clinicians, building on our best-in-class per...
Source: MDDI - December 28, 2018 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Business Source Type: news
